title: Ability of a nondepleting anti-CD4 antibody to inhibit Th2 responses and allergic lung inflammation is independent of coreceptor function.
abstract: Nondepleting anti-CD4 Abs have been used in vivo to induce Ag-specific immunological tolerance in Th1 responses, including tissue allograft rejection and autoimmune diabetes. To examine whether this Ab (YTS177.9) acts by provoking a Th2 shift, we tested the effect in a mouse model of allergic lung inflammation. Interestingly, nondepleting anti-CD4 treatment induces tolerance to allergens as well, especially when given during initial priming. In vitro studies indicate that the effect of the Ab is independent of CD4 coreceptor function, as Ab treatment also inhibits proliferation and induces a persistent anergy in naive CD4 T cells stimulated by anti-CD3/CD28. Moreover, the Ab stimulated a distinct pattern of tyrosine phosphorylation in T cells even in the absence of TCR triggering, suggesting that signaling through CD4 alone induces significant physiological changes in T cell function. These results show that tolerance induced by anti-CD4 triggering is not a simple shift in Th1/Th2 effector function or depletion of Ag-specific cells, but may instead induce a persistent clonal anergy capable of blocking subsequent immunity.
authors.affiliation: Department of Immunology IMM-25, The Scripps Research Institute, La Jolla, CA 92037, USA.
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: M
authors.initials: M
authors.lastname: Crowley
authors.forename: A
authors.initials: A
authors.lastname: Nguyen
authors.forename: D
authors.initials: D
authors.lastname: Lo
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D015704:CD4 Antigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D017635:Clonal Anergy; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007249:Inflammation / Q000276:immunology / Q000517:prevention & control; D007424:Intracellular Fluid / Q000276:immunology / Q000378:metabolism; D008168:Lung / Q000276:immunology / Q000473:pathology*; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D010766:Phosphorylation; D011948:Receptors, Antigen, T-Cell / Q000502:physiology*; D012130:Respiratory Hypersensitivity / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism; D014443:Tyrosine / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D018984:Epitopes, T-Lymphocyte; D007166:Immunosuppressive Agents; D011948:Receptors, Antigen, T-Cell; D014443:Tyrosine; D010047:Ovalbumin